← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT07287644
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Trial Parameters
Condition Hidradenitis Suppurativa (HS)
Sponsor Bluefin Biomedicine, Inc.
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 210
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-11-03
Completion 2027-08-01
Interventions
BFB759Placebo for BFB759
Brief Summary
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Eligibility Criteria
Inclusion Criteria: * Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year. * Have moderate to severe disease not well controlled by systemic antibiotic treatment. * Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study. Exclusion Criteria: * Have certain infections or other immune conditions. * Recently used medications that could interfere with the study. * Are pregnant or breastfeeding.
Related Trials
NCT07287644
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
View Trial →
NCT07109765
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
View Trial →
NCT07021495
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKIN
View Trial →